argenx SE (ARGX)
973.01
+13.52
(+1.41%)
USD |
NASDAQ |
Sep 28, 16:00
973.01
0.00 (0.00%)
After-Hours: 16:43
argenx Research and Development Expense (TTM) : 1.640B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.640B |
| December 31, 2025 | 1.355B |
| June 30, 2025 | 1.165B |
| December 31, 2024 | 975.49M |
| June 30, 2024 | 843.45M |
| December 31, 2023 | 755.11M |
| June 30, 2023 | 643.14M |
| December 31, 2022 | 560.67M |
| June 30, 2022 | 579.83M |
| December 31, 2021 | 575.45M |
| June 30, 2021 | 470.53M |
| Date | Value |
|---|---|
| December 31, 2020 | 386.87M |
| June 30, 2020 | 319.00M |
| December 31, 2019 | 218.45M |
| June 30, 2019 | 143.80M |
| December 31, 2018 | 97.71M |
| June 30, 2018 | 71.78M |
| December 31, 2017 | 58.25M |
| June 30, 2017 | 49.83M |
| December 31, 2016 | 34.42M |
| June 30, 2016 | 24.77M |
| December 31, 2015 | 22.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Autolus Therapeutics Plc | 112.42M |
| Forte Biosciences, Inc. | 79.74M |
| Akari Therapeutics Plc | 4.869M |
| Grifols SA | 477.82M |
| Evaxion AS | 10.27M |